Want to see EVO full AI Analyst Report?
EVO Stock Chart & Stats
$1.89
-$0.04(-2.02%)
At close: 4:00 PM EDT
$1.89
-$0.04(-2.02%)
Day’s Range― - ―
52-Week Range$1.50 - $4.27
Previous CloseN/A
Volume33.59K
Average Volume (3M)119.49K
Market Cap
$618.96M
Enterprise Value$1.01K
Total Cash (Recent Filing)$465.59M
Total Debt (Recent Filing)$475.87M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend Yield4.93%
Share Statistics
EPS (TTM)-0.56
Shares Outstanding355,819,950
10 Day Avg. Volume260,809
30 Day Avg. Volume119,491
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.80Price Target Upside48.15% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$692.02M
Bulls Say, Bears Say
Bulls Say
Integrated Discovery PlatformEvotec’s broad, integrated capabilities allow partners to access multiple stages of drug discovery and development through one platform. This can deepen customer relationships, support recurring contracted work, and improve cross-selling across disease areas over the medium term.
Biologics And Biodefense ExpansionAdvancing JST-018 into a first-in-human trial demonstrates that Evotec’s biologics platform can support programs from sequence selection through manufacturing and regulatory submission. U.S. biodefense work adds strategic demand and reinforces the value of its scalable capabilities.
Partnership And Platform OptionalityNew collaborations, grants, milestones and the J.TRAIN launch broaden Evotec’s commercial and scientific ecosystem. These relationships can provide contracted funding while preserving milestone and downstream participation, creating longer-term revenue optionality beyond fee-for-service work.
Bears Say
Revenue And EBITDA DeteriorationThe sharp first-half revenue decline and negative adjusted EBITDA indicate that Evotec is currently struggling to convert its platform and contracts into profitable growth. Persistent underperformance could weaken operating leverage and reduce resources available for investment.
Severe Margin CompressionGross-margin compression alongside a substantial net loss suggests weaker economics than in earlier periods, whether from mix, pricing or costs as described in the pack. Without sustained recovery, profitability and the company’s ability to scale earnings remain impaired.
Negative Cash GenerationNegative operating and free cash flow means the business is consuming cash rather than funding operations internally. If this pattern persists, Evotec may have less flexibility to support growth, absorb execution setbacks, or reduce reliance on external financing.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $1.50 and its highest was $4.27 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $618.96M.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Nov 05, 2026 which is in 34 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Aug 13, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.11.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of 4.93%. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.27.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,950 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -7.763%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.80 (48.15% Upside)
$2.80 (48.15% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 67%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVO Company Deck
EVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: near-term financials were weak with material revenue declines (H1 revenues down ~19%) and negative adjusted EBITDA (H1 EUR -42.7m), and management revised full-year 2026 guidance downward due mainly to timing shifts in strategic partnership milestone recognition. Offsetting these weaknesses are encouraging commercial leading indicators (inbound inquiries +~30%, proposals >45%, base D&PD net sales +~28% in H1), a healthy pipeline of 10–20 strategic partnership opportunities, strong liquidity (EUR 465.6m), active cost-savings via the Horizon program (~EUR 75m run-rate by 2027), and recent senior hires to improve commercial conversion. Overall, the issues appear driven largely by timing and phasing rather than loss of pipeline quality, but 2026 results and guidance remain meaningfully impacted.View all EVO earnings summariesEVO Stock 12 Month Forecast
Average Price Target
$2.80
▲(48.15% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.63% Other Institutional Investors
99.37% Public Companies and
Individual Investors